Last €46.67 EUR
Change Today -0.335 / -0.71%
Volume 200.0
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:21 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1000 Mylan Boulevard

Canonsburg, PA 15317

United States

Phone: 724-514-1800

Fax:

Mylan Inc., together with its subsidiaries, operates as a pharmaceutical company worldwide. The company develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals. It also has a specialty business that is focused on respiratory and allergy therapies. The company markets a global portfolio of approximately 1,300 different products to customers in approximately 140 countries and territories covering a range of therapeutic categories. The company offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while focusing on those products that are difficult to formulate and manufacture, and have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, the company offers a range of antiretroviral therapies (ARVs), upon which majority of HIV/AIDS patients in developing countries depend. It also operates an API manufacturer supplying API for its own products and pipeline, as well as for various third parties. Segments The company operates through two segments, Generics and Specialty. The company’s generic pharmaceutical business is conducted primarily in the U.S. and Canada (collectively, ‘North America’); Europe, the Middle East, and Africa (collectively, ‘EMEA’); and India, Australia, Japan, New Zealand, and Brazil (collectively, ‘Rest of World’). The company’s API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Rest of World in its Generics segment. GENERICS North America The company’s sales in the U.S. are derived primarily from the sale of oral solid dosage, injectable and transdermal products and unit dose offerings. In the U.S., the company has one of the primary product portfolios among all generic pharmaceutical companies, consisting of approximately 320 products, of which approximately 260 are in capsule or tablet form in an aggregate of approximately 790 dosage strengths. Included in these totals are approximately 40 extended-release products in a total of approximately 100 dosage strengths. The company manufactures and sells a portfolio of injectable products across various major therapeutic areas, including antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. Its product offerings include a portfolio of approximately 60 injectable products (branded and generic) in a total of approximately 130 dosage strengths. With the acquisition of Agila Specialties business (Agila), the company brings a portfolio to the injectables market, including doubling its injectables portfolio to 120 products. Through its acquisition of Agila, the company also acquired a 50% equity interest in Sagent Agila LLC (Sagent Agila). Sagent Agila is engaged in the development, manufacturing, and distribution of certain generic injectable products in the U.S. market. The company’s unit dose business focuses on providing product portfolio along with packaging and barcoding that supports bedside verification for customers throughout the U.S. and Canada. These customers include hospitals, group purchasing organizations (GPOs), long term care facilities, wholesalers, surgical services, home infusion service providers, correctional facilities, specialty pharmacies, and retail outlets. In addition to the products that the company packages in the U.S., it markets approximately 60 generic products in a total of approximately 85 dosage strengths under supply and distribution agreements with wholesalers. Also included in the company’s U.S. product portfolio are 4 transdermal patch products in a total of 18 dosage strengths. Its Fentanyl Transdermal System (Fentanyl) is the first AB-rated generic alternative to Duragesic on the market and is also the first generic class II narcotic transdermal product ever approved. The company’s Fentanyl product remains the only AB-rated generic alternative approved in all strengths. In Canada, the company offers a portfolio of approximately 150 products in an aggregate of appr

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:GR €46.67 EUR -0.335

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $69.99 USD +0.39
Perrigo Co PLC $159.22 USD +2.75
UCB SA €62.54 EUR +0.18
WW Grainger Inc $247.16 USD -2.08
WESCO International Inc $85.14 USD -0.52
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 25.3x
Price/Sales 2.9x
Price/Book 6.5x
Price/Cash Flow 23.8x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.